Thymopentin for injection

This product is an immune bidirectional regulator. It has the function of inducing and promoting the differentiation, maturation and activation of T lymphocytes and their subgroups, regulating the ratio of T lymphocytes to make CD4/CD8 tend to normal; regulating and enhancing the cellular immune function of the human body, which can promote the maturation of T lymphocytes in peripheral blood after mitogen activation, increase the secretion of various lymphokines (such as alpha, gamma interferon, interleukin 2 or interleukin 3) after T cells are activated by various antigens or mitogens, and increase the level of lymphokine receptors on T cells. It also enhances lymphocyte response by activating T helper cells. In addition, this product may affect the chemotaxis of NK precursor cells, which become more cytotoxic after exposure to interferon, which is conducive to its therapeutic effect. In addition, this product can enhance the body's ability to resist radiation. Therefore, this product has the function of regulating and enhancing the cellular immune function of the human body.

The main ingredient of this product is thymopentin.

This product is suitable for: malignant tumor patients with low immune function caused by radiotherapy and chemotherapy. (1) For patients with chronic hepatitis B over 18 years old. (2) Various primary or secondary T cell deficiency diseases (such as congenital immunodeficiency in children). (3) Certain autoimmune diseases (such as rheumatoid arthritis, systemic lupus erythematosus, etc.). (Lupus erythematosus is an autoimmune disease with a slow onset and insidious occurrence. The clinical manifestations are diverse and varied. It is an autoimmune disease involving many systems and organs. Due to the dysfunction of cellular and humoral immune function, a variety of autoantibodies are produced. It can affect the skin, serous membranes, joints, kidneys and central nervous system, etc., and is characterized by autoimmunity. There are multiple autoantibodies in the patient's body, which not only affect humoral immunity, but also cellular immunity, and the complement system also changes. The pathogenesis is mainly due to the formation of immune complexes. The exact cause is unknown. The condition is a process of repeated attacks and remissions.) (4) Various diseases with low cellular immune function. (5) Adjuvant treatment of tumors.

For intramuscular injection, dissolve in 1 ml of sterile water for injection before use or dissolve in 250 ml of 0.9% sodium chloride injection and slowly drip intravenously alone, 1 vial at a time, 1 to 2 times a day, 15 to 30 days as a course of treatment, or follow the doctor's advice.

1. Good tolerance, some patients may experience adverse reactions such as nausea, fever, dizziness, chest tightness, weakness, etc., and a few patients may occasionally feel drowsy. 2. When used by patients with chronic hepatitis B, ALT levels may rise temporarily. If there are no signs of liver failure, they can continue to use this product.

1. It is contraindicated for patients who need immunosuppression in the early stage of organ transplantation; 2. It should be used with caution in pregnant women.

Precautions during pregnancy and lactation: Pregnant patients should use with caution.

(1) This product can be used in combination with many commonly used drugs, including interferon, anti-inflammatory drugs, antibiotics, hormones, analgesics, antihypertensive drugs, diuretics, drugs for the treatment of cardiovascular diseases, central nervous system drugs, and contraceptives, without any interference. (2) This product has a synergistic effect in improving immune function when used in combination with interferon.

Keep away from light and store in sealed container.

1mg

24 months.

Nanjing Cuccess Pharmaceutical Co., Ltd.

• Founded in:

  2002-03-20

• Address:

  No. 20, Xingang Avenue, Nanjing Economic and Technological Development Zone

• Tax NO.:

  913201926089285606

• Registered Funds:

  60 million yuan

• Website:

  Log in to view

• Email:

  Log in to view